AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal
Sees Potential Beyond Vaccines
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
